

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 April 2008 (03.04.2008)

PCT

(10) International Publication Number
WO 2008/039645 A1

(51) International Patent Classification:

C07C 317/44 (2006.01) **C07D 261/12** (2006.01)
A61K 31/16 (2006.01) **C07D 277/46** (2006.01)
A61P 29/00 (2006.01) **C07D 277/82** (2006.01)
A61P 37/00 (2006.01) **C07D 309/04** (2006.01)
C07D 213/75 (2006.01) **C07D 403/12** (2006.01)
C07D 215/38 (2006.01) **C07D 405/12** (2006.01)
C07D 217/22 (2006.01) **C07D 407/12** (2006.01)
C07D 231/40 (2006.01)

(21) International Application Number:

PCT/US2007/078341

(22) International Filing Date:

13 September 2007 (13.09.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/826,819 25 September 2006 (25.09.2006) US

(71) Applicant (for all designated States except DE, US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, D-55216 Ingelheim (DE).

(71) Applicant (for DE only): **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Strasse 173, D-55216 Ingelheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERRY, Angela** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **CIRILLO, Pier Francesco** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **HICKEY, Eugene Richard** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **RIETHER, Doris** [AT/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **THOMSON, David** [GB/US]; Boehringer Ingelheim Pharmaceuticals,

Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **ZINDELL, Renee M.** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **ERMANN, Monika** [AT/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **JENKINS, James Edward** [GB/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **MUSHI, Innocent** [TZ/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **TAYLOR, Malcolm** [GB/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **CHOWDHURY, Chandana** [GB/GB]; 4 Trident Park, Didcot, Oxfordshire OX11 7HJ (GB). **PALMER, Christopher Francis** [GB/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **BLUMIRE, Nigel** [GB/GB]; 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB).

(74) Agents: **MORRIS, Michael, P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR



(57) Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.